The effectiveness of the use of the anti-inflammatory vaginal solution of ibuprofen isobutylammonium for the reduction in the severity of inflammation of the lower genital tract in women with surgical pathologies of the pelvis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. In gynecological practice, in order to reduce the severity of inflammatory processes in the lower genital tract, surgical intervention requires more careful preparation, since all measures are aimed at restoring the woman's reproductive function in the future. In clinical trials, the effectiveness of the anti-inflammatory solution used in addition to the standard preparatory regimen in the preoperative period has been proved in patients with inflammatory pathologies of the lower genital tract. Objective. Evaluation of the effectiveness of topical application of the vaginal solution of ibuprofen isobutylammonium for the prevention of local and systemic inflammation during surgical treatment of pelvic diseases. Methods. A randomized comparative clinical study included 60 patients aged 20 to 65 years hospitalized for surgical pelvc pathology with concomitant genital tract inflammation. Patients were diveded into 2 groups of 30 people. In the control group, patients underwent standard 2-day preoperative preparation. In the main group, patients received vaginal solution of ibuprofen isobutylammonium once a day in the morning for two days (the solution was poured into the vagina for 3-5 minutes) in addition to the standard preoperative preparation. To assess the dynamics of the clinical signs of inflammation and symptoms, we used the somatic symptom scale (SSS) and the adapted visual analogue scale (VAS). Evaluation was performed before treatment and after 2 days of treatment. Results. The characteristics of the patients registered before the start of treatment did not statistically significantly differ. The reasons for hospitalization and subsequent surgical treatment included inflammatory pelvic diseases in 27 (45%) patients, uterine fibroids - in 24 (40%), pelvic organ prolapse - in 6 (10%), pathological changes in the endometrium - 7 (12%); 6 (10%) patients had a combination of several main pathologies. Inflammation of the lower genital tract, which was evaluated according to three objective criteria, was strongly pronounced in all patients. In the main group, the additional use of vaginal solution of ibuprofen isobutylammonium compared with standard therapy significantly decreased (by 47-70%) the inflammation of lower genital tract, 1.5 times more effectively reduced the severity of disturbing patients with vaginal symptoms, and provided 2-12 times more rapid disappearance of these symptoms. There were no adverse reactions with the use of this preparation. Conclusion. The vaginal solution of ibuprofen isobutylammonium can be used as a convenient adjuvant preparation in the management of patients with surgical pelvic pathology.

Full Text

Restricted Access

About the authors

D. K Nazhmutdinova

Tashkent Medical Academy

Email: sv_irena@mail.ru
Dr. Sci. (Med.), Professor at the Department of Obstetrics and Gynecology

D. D Kurbanov

Tashkent Pediatric Medical Institute

R. S Navruzova

Tashkent Pediatric Medical Institute

I. V Ishchenko

Tashkent Pediatric Medical Institute

References

  1. Preoperative Considerations. In: Williams Gynecology [ed. by Hoffman B.L. et al.], 3rd ed. McGraw-Hill Education: New York (NJ, USA); Ch. 39. 2016. 825 p.
  2. Mangano D.T. Perioperative medicine: NHLBI working group deliberations and recommendations. J Cardiothorac Vasc Anesth. 2004;18(1):1-6. doi: 10.1053/j.jvca.2003.10.002.
  3. Patient assessment, consent and preparation for surgery. In: Bonney'sGynaecological Surgery [Monaghan J.M. et al.], 10th ed. Blackwell Publishing Company: Malden (MA, USA); Ch.3. 2004. P 25.
  4. Lachiewicz M.P, Moulton L.J., Jaiyeoba O. Pelvic surgical site infections in gynecologic surgery. Infect Dis Obstet. Gynecol. 2015;2015:614950. doi: 10.1155/2015/614950.
  5. Wiesenfeld H., Hillier S.L., Krohn M.A., et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet&Gynecol. 2002,100(3):456-63. doi: 10.1016/s0029-7844(02)02118-x.
  6. Wiesenfeld H.C., Hillier S.L., Meyn L.A., et al. Subclinical pelvic inflammatory disease and infertility. Obstet Gynecol. 2012;120(1):37-43. Doi: W.W97/AOG.0b013e31825a6bc9.
  7. Wiesenfeld H.C., Sweet R.L., Ness R.B., et al. Comparison of Acute and Subclinical Pelvic Inflammatory Disease. Sex Trans Dis.2005;32(7):400-5. doi: 10.1097/01. olq.0000154508.26532.6a.
  8. Yudin M.H., Hillier S.L., Wiesenfeld H.C., et al. Vaginal polymorphonuclear leukocytes and bacterial vaginosis as markers for histologic endometritis among women without symptoms of pelvic inflammatory disease. Am J Obstet Gynecol. 2003;188(2):318-23.
  9. Terao M, Koga K, Fujimoto A, Wada-Hiraike O., et al. Factors that predict poor clinical course among patients hospitalized with pelvic inflammatory disease. J Obstet Gynaecol Res. 2014;40(2):495-500. doi: 10.1111/jog.12189.
  10. Boesch C.E., Pronk R.F., Medved F, et al. Do prophylactic antibiotics in gynecologic surgery prevent postoperative inflammatory complications? A systematic review. Arch Gynecol Obstet. 2017;295(6):1383-91.
  11. Jaiyeoba O. Postoperative infections in obstetrics and gynecology. Clin Obstet Gynecol. 2012;55(4):904-13. Doi: 10.1097/ GRF.0b013e3182714734.
  12. Инструкция по медицинскому применению лекарственного средства Гиненорм 0,1% вагинальный раствор 100 мл, одобрение Главного управления по контролю качества ЛС и МТ МЗ РУз № 28 от 09.12.2015. [Instructions for the medical use of the drug Ginenorm 0,1% vaginal solution 100 ml, approval of the General Directorate for Quality Control of Medicines and MT Ministry of Health of the Republic of Uzbekistan No. 28 dated 12/09/2015. (In Russ.)].
  13. Milani M., Iacobelli P. Vaginal use of Ibuprofen isobutanolammonium (ginenorm): efficacy, tolerability, and pharmacokinetic data: a review of available data. ISRN Obstet Gynecol. 2012;2012(673131):1-6. doi: 10.5402/2012/673131.
  14. Самигулина А.Э., Максутов аЭ.М., Сарыбаева К.А. Оценка эффективности вагинально -го раствора ибупрофена изобутиламмония при лечении вагинитов. Здоровье матери и ребенка. 2016;8(1):51-9. [Samigulina A.E., Maksutova E.M., Sarybaeva K.A. Evaluation of the effectiveness of the vaginal solution of ibuprofen isobutylammonium in the treatment of vaginitis. Zdorov'e materi i rebenka.2016;8(1):51-9. (In Russ.)].
  15. Sullivan G.M., Artino A.R. Analyzing and Interpreting Data FromLikert-Type Scales. J Grad Med Educ. 2013;5(4):541-42. Doi: 10.4300/ JGME-5-4-18.
  16. Stinson J.N., Kavanagh T., Yamada J., et al. Systematic review of the psychometric properties, interpretability and feasibility of self-report pain intensity measures for use in clinical trials in children and adolescents. Pain. 2006;125(1-2):143-57. doi: 10.1016/j.pain.2006.05.006.
  17. Witt A., Kaufmann U., Bitschnau M., et al. Monthly itraconazole versus classic homeopathy for the treatment of recurrent vulvovaginal candidiasis: a randomised trial. BJOG. 2009;116(11):1499-505. doi: 10.1111/j.1471-0528.2009.02262.x.
  18. Todd K.H., Funk J.P The minimum clinically important difference in physician-assigned visual analog pain scores. Acad Emerg Med. 1996;3(2):142-46. doi: 10.1111/j.1553-2712.1996.tb03402.x.
  19. Pickard A.S., Neary M.F!, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70. doi: 10.1186/14777525-5-70.
  20. Bodian C.A., Freedman G., Hossain S., et al. The visual analog scale for pain: clinical significance in postoperative patients. Anesthesiology. 2001;95(6):1356-61. doi: 10.1097/00000542-200112000-00013.
  21. Durham T.A., Turner J.R. Sample size for continuous outcomes in superiority trials. In: Introduction to Statistics in Pharmaceutical Clinical Trials. Pharmaceutical Press: London (UK); Ch. 12. 2008. Р 173-74.
  22. Candiani G.B. Therapeutic effect and tolerability of the formula "SC501"packets of 1 g in inflammatory processes of the vulvovaginal complex (controlled study vs. placebo) IstitutiClinici di perfezionamento "L. Mangiagalli" Obstetrics and Gynecology Clinic, University of Milan. Prima Clinica, Milan. 1987.
  23. Dean A.G., Sullivan K.M., Soe M.M. Open Epi: Open Source Epidemiologic Statistics for Public Health, version 3.03. www.OpenEpi.com, upd.2014/09/22, accessed 2019/05/26.
  24. Bonnet F, Marret E. Postoperative pain management and outcome after surgery. Best Pract Res Clin Anaesthesiol. 2007;21(1):99-107. doi: 10.1016/j.bpa.2006.12.007.
  25. Glassou E.N., et al. Impact of preadmission anti-inflammatory drug use on the risk of RBC transfusion in elderly hip fracture patients: a Danish nationwide cohort study, 2005-2016. Transfusion. 2019;59(3):935-44. doi: 10.1111/ trf.15110.
  26. Glassou E.N., et al. Impact of preadmission anti-inflammatory drug use on the risk of RBC transfusion in elderly hip fracture patients: a Danish nationwide cohort study, 2005-2016. Transfusion. 2019;59(3):935-44. doi: 10.1111/ trf.15110.
  27. Lewis S.R., et al. Nonsteroidal anti-inflammatory drugs and perioperative bleeding in paediatric tonsillectomy. Cochrane Database Syst Rev. 2013;(7):CD003591. doi: 10.1002/14651858. CD003591.pub3.
  28. Kryger Z.B., et al. Safety issues in combined gynecologic and plastic surgical procedures. Int J Gynaecol Obstet. 2007;99(3):257-63. doi: 10.1016/j.ijgo.2007.05.028.
  29. Nyirjesy I3 Management of persistent vaginitis. Obstet Gynecol. 2014;124(6):1135-46. doi: 10.1097/A0G.0000000000000551.
  30. Powell A.M., Nyirjesy P Recurrent vulvovaginitis. Best Pract Res Clin Obstet Gynaecol. 2014;28(7):967-76. Doi: 10.1016/j. bpobgyn.2014.07.006.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies